H ypercholesterolemia stimulates components of the renin-angiotensin system (RAS), including angiotensin type 1 (AT 1 ) receptors 1, 2 and systemic concentrations of angiotensin peptides. 3 Moreover, pharmacological interference with the RAS through inhibition of angiotensinconverting enzyme (ACE), renin, or AT 1 receptors has been demonstrated to reduce both experimental and human atherosclerosis. 4 -6 Similarly, genetic manipulation of the RAS, including AT 1a receptors 3, 7 or ACE deficiency, 8, 9 caused a striking reduction in experimental atherosclerosis, further supporting a role for the RAS in atherosclerosis. Recent studies in our laboratories demonstrated that deficiency of renin in bone marrow-derived stem cells reduced hypercholesterolemia-induced atherosclerosis in low-density lipoprotein receptor-deficient (Ldlr Ϫ/Ϫ ) mice, suggesting that leukocyte production of angiotensin peptides influenced developing atherosclerotic lesions. 6 Collectively, results support a prominent role of the RAS in developing atherosclerotic lesions; however, the relative importance of systemic versus local production of angiotensin peptides in lesion formation has not been fully resolved.
ACE2, a more recently discovered member of the RAS that has 40% homology to ACE, 10 -12 is a monocarboxypeptidase that cleaves the vasoconstrictor angiotensin II (Ang II) to a vasodilatory peptide, angiotensin 1-7 (Ang-(1-7)). ACE2 is located on the sex-linked X chromosome and exhibits widespread tissue distribution. 10, 13 Although ACE2 can catabolize angiotensin I, it has greater catalytic efficiency in the catabolism of Ang II (Ϸ400-fold higher). 12 On the basis of its ability to degrade the vasoconstrictor Ang II and produce the vasodilator Ang-(1-7), ACE2 has been suggested to limit pathophysiologic activation of the RAS.
Previous studies localized ACE2 to atherosclerotic lesions of rabbit aorta and human carotid arteries. 14, 15 Interestingly, ACE2 localized to smooth muscle, endothelial cells, and macrophages in lesions of hypercholesterolemic rabbits. 15 Functional studies have demonstrated that overexpression of ACE2 using adenoviral transfection in apolipoprotein E Ϫ/Ϫ (ApoE Ϫ/Ϫ ) mice or in hypercholesterolemic rabbits decreased atherosclerosis. 16, 17 Recent studies demonstrated that whole body ACE2 deficiency increased atherosclerosis in ApoE Ϫ/Ϫ mice. 18 In this study, we examined effects of whole body or leukocytic ACE2 deficiency on high-fat (HF) diet-induced atherosclerosis in Ldlr Ϫ/Ϫ mice. To define mechanisms of ACE2 to regulate lesion formation, we focused on interactions between Ang II and Ang-(1-7) as the substrate and product of ACE2, respectively, in the regulation of monocyte adhesion to endothelial cells and on lesion development.
Methods
A detailed description of the methods section is provided in the Supplemental Materials, available online at http://atvb.ahajournals.org.
To examine effects of whole body ACE2 deficiency on atherosclerosis, male Ace2 ϩ/y and Ace2 Ϫ/y mice on an Ldlr Ϫ/Ϫ background (no. 002207, obtained from the Jackson Laboratory, Bar Harbor, ME) were fed a HF diet (42% caloric intake from fat, TD88137, Harlan Teklad, Indianapolis, IN) for 3 months. In separate studies, losartan was administered by osmotic minipump (25 mg/kg per day SC) to Ace2 Ϫ/y male mice during month 3 of HF feeding. For bone marrow transplantation, male Ldlr Ϫ/Ϫ mice (2 months of age) were irradiated with a total of 900 rads from a cesium source delivered in 2 doses. 2 Mice were maintained on antibiotic water (sulfatrim, 4 g/mL) for 1 week before and 6 weeks after irradiation before feeding the HF diet for an additional 3 months. To define interactions between Ang-(1-7) and Ang II in the regulation of lesion formation, Ang-(1-7) (400 ng/kg per minute) was infused to fat-fed Ldlr Ϫ/Ϫ male mice for 7 days before coinfusion of Ang II (1000 ng/kg per minute) for 28 days. Macrophages were harvested from the peritoneum of Ace2 ϩ/y or Ace2 Ϫ/y Ldlr Ϫ/Ϫ mice. All studies were approved by the Institutional Animal Care and Use Committee at the University of Kentucky.
Results

Whole Body ACE2 Deficiency Increased Atherosclerosis in Ldlr ؊/؊ Mice
Deficiency of ACE2 (insertion of a neomycin cassette in exon 9 of the ACE2 gene 19 ) was confirmed by ablation of mRNA of ACE2 in kidneys of Ace2 ϩ/Ϫ and Ace2 Ϫ/Ϫ female mice ( Figure 1A ). Deficiency of ACE2 had no effect on body weight, systolic blood pressure, serum ACE activity, plasma renin concentrations, serum cholesterol concentrations, or lipoprotein cholesterol distributions in Ldlr Ϫ/Ϫ mice fed an HF diet (Table, Supplemental Figure IIA ). Plasma concentrations of Ang II were modestly but not significantly increased in Ace2 Ϫ/y mice fed a HF diet (1 month of HF feeding: Ace2 ϩ/y , 29Ϯ4; Ace2 Ϫ/y , 39Ϯ6 pg/mL; PϾ0.05). Whole body deficiency of ACE2 increased lesion area in aortic arches ( Figure 1B and 1D, PϽ0.002) and aortic sinuses ( Figure 1E , PϽ0.05) compared with Ace2 ϩ/y wild-type controls. Quantification of CD68 immunostaining revealed that macrophage accumulation was greater in aortic sinus lesions from Ace2 Ϫ/y mice compared with Ace2 ϩ/y Ldlr Ϫ/Ϫ controls (Ace2 ϩ/y , 0.25Ϯ0.02; Ace2 Ϫ/y , 0.44Ϯ0.04 mm 2 ; PϽ0.007) (Figure 1F ). Administration of the AT 1 receptor antagonist losartan to Ace2 Ϫ/y mice decreased lesion formation in aortic arches ( Figure 1C and 1D) and sinuses (Supplemental Figure IA) .
To define cell types implicated in effects of ACE2 deficiency, aortic sinus sections from Ace2 ϩ/y Ldlr Ϫ/Ϫ mice were immunostained for ACE2 or CD68 ( Figure 2 ). Lesions with pronounced CD68 immunostaining also exhibited ACE2 immunoreactivity. In addition, ACE2 immunoreactivity was also evident in media and adventitia of aortic sinuses. Because ACE2 immunoreactivity localized to macrophages of lesions, we assessed ACE2 enzymatic activity in macrophages harvested from the peritoneal cavity (mouse peritoneal macrophages). ACE2 enzymatic activity in mouse peritoneal macrophages was similar to that in heart and liver (Supplemental Figure IB ).
ACE2 Deficiency in Bone Marrow-Derived Cells Increased Atherosclerosis in Ldlr ؊/؊ Mice
Because lesional macrophages stained positive for ACE2, we repopulated irradiated Ldlr Ϫ/Ϫ mice with bone marrowderived cells harvested from either Ace2 ϩ/y or Ace2 Ϫ/y mice to define the role of leukocyte ACE2. After 6 weeks of repopulation, mice in each group were fed a HF diet for 3 months. Genomic analyses of irradiated mice demonstrated effective repopulation with Ace2 ϩ/y or Ace2 Ϫ/y donor cells (Supplemental Figure III) . Deficiency of ACE2 in bone marrow-derived cells had no effect on body weight, systolic blood pressure, serum ACE activity, plasma renin concentration, serum cholesterol concentration, or lipoprotein choles-terol distribution (Table and Supplemental Figure IIB ). ACE2 deficiency in bone marrow-derived cells increased lesion areas in both aortic arches (Ace2 ϩ/y , 1.6Ϯ0.3; Ace2 Ϫ/y , 2.8Ϯ0.3 mm 2 ; PϽ0.05, Figure 3A ) and aortic sinuses ( Figure  3B ; PϽ0.05). In addition, CD68-positive immunostaining was increased in sections from aortic sinus of mice transplanted with Ace2 Ϫ/y compared with Ace2 ϩ/y marrow ( Figure  3C and 3D).
Peritoneal Macrophages From ACE2-Deficient Mice Exhibited Increased Expression of Inflammatory Cytokines and Promoted Monocyte Adhesion to Endothelial Cells
Concentrations of Ang II released from MPMs of Ace2 Ϫ/y mice were increased compared with Ace2 ϩ/y cells (Ace2 ϩ/y , 70Ϯ8; Ace2 Ϫ/y , 115Ϯ13 pg/mL; PϽ0.05, Figure 4A ). To determine whether elevated Ang II concentrations influenced inflammatory cytokines, we examined mRNA abundance and culture media protein levels of various inflammatory cytokines and their receptors using MPMs harvested from Ace2 ϩ/y or Ace2 Ϫ/y Ldlr Ϫ/Ϫ mice. In MPMs from Ace2 Ϫ/y mice, mRNA abundance of C-C motif chemokine receptor 2 was increased ( Figure 4B ), and protein concentrations of interleukin 6 and plasminogen activator inhibitor 1 released into culture media were elevated ( Figure 4C ). In addition, deficiency of ACE2 resulted in modest elevations in mRNA abundance or protein release of CCL2, tumor necrosis factor-␣ and its receptor, and nuclear factor-B (Supplemental Tables II and III) . To determine whether MPMs from Ace2 Ϫ/y mice promoted monocyte adhesion to endothelial cells, 6 we cocultured human umbilical vein endothelial cells (HUVECs) and MPMs from Ace2 ϩ/y and Ace2 Ϫ/y mice by placing cells in the upper and lower chamber of Transwells, respectively. Human monocytic leukemia cell line 1 monocytes were placed in the upper chamber to assay for adhesion to HUVECs. Coculture of MPMs from Ace2 Ϫ/y mice with HUVECs resulted in increased THP-1 monocyte adhesion compared with coculture with MPMs from Ace2 ϩ/y controls (Ace2 ϩ/y , 100Ϯ7; Ace2 Ϫ/y , 142Ϯ13% control; PϽ0.05; Figure 4D) . Losartan reduced THP-1 monocyte adhesion when HUVECs were cocultured with MPMs from Ace2 ϩ/y or Ace2 Ϫ/y mice; however, losartan-mediated reductions in monocyte adhesion were more pronounced when HUVECs were cocultured with MPMs from Ace2 Ϫ/y (4-fold) compared with Ace2 ϩ/y mice (2-fold) ( Figure 4D ). In contrast, the Ang-(1-7) mas receptor antagonist, D-Ala, did not signifi-cantly influence THP-1 monocyte adhesion when HUVECs were cocultured with MPMs from Ace2 ϩ/y or Ace2 Ϫ/y mice ( Figure 4D ).
The ACE2 Product Ang-(1-7) Functionally Antagonized Ang II-Induced Monocyte Adhesion to HUVECs and Reduced Ang II-Induced Atherosclerosis in Ldlr ؊/؊ Mice
Recent studies demonstrated that Ang-(1-7) antagonized effects of Ang II to promote vascular smooth muscle cell proliferation and migration. 20 Therefore, we investigated the relative contribution of the ACE2 substrate, Ang II, to the ACE2 product, Ang-(1-7), in the regulation of monocyte adhesion to HUVECs. Incubation of HUVECs with Ang II increased monocyte adhesion, and this effect was abolished by losartan ( Figure 5A ). By itself, Ang-(1-7) had no effect on monocyte adhesion. However, Ang-(1-7) functionally antagonized Ang II-induced stimulation of monocyte adhesion ( Figure 5A ), and this effect was blocked by D-Ala. To determine whether these peptides interacted in vivo in the regulation of atherosclerosis, we infused Ldlr Ϫ/Ϫ mice with Ang II in the absence or presence of coinfused Ang-(1-7). Coinfusion of Ang-(1-7) with Ang II reduced (2-fold) atherosclerosis in the aortic arch ( Figure 5B and 5E) and sinus ( Figure 5D ) and decreased CD68 immunostaining in aortic sinus sections ( Figure 5C ). 
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Discussion
Results from this study demonstrate that whole body deficiency of ACE2 increased the development of atherosclerosis in fat-fed Ldlr Ϫ/Ϫ mice. ACE2 localized to macrophage-rich regions of atherosclerotic lesions, and ACE2 enzymatic activity was evident in mouse peritoneal macrophages. Interestingly, deficiency of ACE2 in bone marrow-derived cells also promoted the development of atherosclerosis. Although plasma concentrations of Ang II were not markedly elevated in whole body ACE2-deficient mice, macrophages from ACE-2 deficient mice released greater concentrations of Ang II. Moreover, macrophages from ACE2-deficient mice exhibited increased expression and release of inflammatory cytokines and promoted monocyte adhesion to endothelial cells. Although Ang-(1-7) had no effect on monocyte adhesion by itself, this angiotensin peptide functionally antagonized Ang II-induced stimulation of monocyte adhesion and lesion formation. These results demonstrate that ACE2 deficiency promotes atherosclerosis and suggest that endogenous ACE2 protects against atherosclerosis by controlling the relative balance between Ang II and Ang-(1-7) in pivotal cell types. We found that cultured macrophages from ACE2-deficient mice release greater concentrations of Ang II. In contrast, whole body deficiency of ACE2 had no effect on systemic concentrations of renin or Ang II. Our results are in agreement with several studies that document no change in plasma or kidney angiotensin peptide concentrations in ACE2deficient mice. 21, 22 However, it should be noted that a previous study reported that ACE2 deficiency increased systemic concentrations of Ang II in mice experiencing heart failure. 13 An interesting aspect of the present study is that whole body and bone marrow cell deficiency of ACE2 promoted atherosclerosis but had no effect on the systemic RAS. These results suggest that ACE2 primarily influences concentrations of Ang II in pivotal cell types involved in developing lesions.
Previous investigators demonstrated that whole body ACE2 deficiency had strain-dependent effects on blood pressure. 19 In C57BL/6 mice, ACE2 deficiency resulted in a modest increase in blood pressure (Ϸ7 mm Hg). 19 We did not observe an effect of ACE2 deficiency on systolic blood pressures in Ldlr Ϫ/Ϫ mice. It is possible that ACE2 deficiency on an Ldlr Ϫ/Ϫ background blunted blood pressure increases in C57BL/6 mice. Previous studies demonstrated that although AT 1a receptor deficiency had divergent effects on systolic blood pressure in Ldlr Ϫ/Ϫ and ApoE Ϫ/Ϫ mice, the loss of AT 1a receptor signaling resulted in pronounced reductions in atherosclerosis. 3, 7 Therefore, it is unlikely that blood pressure . ACE2 deficiency promoted Ang II release, chemokine receptor expression, and inflammatory cytokine release from cultured peritoneal macrophages and increased monocyte adhesion to endothelial cells. A, Ang II release from MPMs of Ace2 ϩ/y or Ace2 Ϫ/y mice. B, C-C motif chemokine receptor 2 mRNA abundance in MPMs from Ace2 ϩ/y or Ace2 Ϫ/y mice (nϭ6 mice per genotype). C, Interleukin 6 (IL-6) and plasminogen activator inhibitor 1 (PAI-1) protein levels released from MPMs of Ace2 ϩ/y or Ace2 Ϫ/y mice (nϭ6 mice per genotype). D, Coculture of MPMs from Ace2 Ϫ/y mice with HUVECs increased THP-1 monocyte adhesion compared with control (expressed as percentage of THP-1 adhesion in macrophage media from Ace2 ϩ/y mice). Coincubation of MPMs from each genotype with losartan (1 mol/L; nϭ3 to 6 mice per genotype) reduced monocyte adhesion, whereas coincubation with D-Ala (5 mol/L; nϭ3 to 6 mice per genotype) had no effect. *PϽ0.05 compared with Ace2 ϩ/y (A to D), †PϽ0.05 compared with vehicle within genotype. effects from ACE2 deficiency contributed to the augmented atherosclerosis observed in the present study.
Our results are in agreement with previous studies demonstrating that ACE2 localized to macrophage-rich areas of atherosclerotic lesions from hypercholesterolemic rabbits. 15 However, these results extend previous findings by demonstrating that murine macrophages exhibit ACE2 enzymatic activity and that macrophages from ACE2-deficient mice release greater concentrations of Ang II. Similar to previous findings demonstrating reductions in thoracic aortic lesion areas following bone marrow transplantation in HF-fed Ldlr Ϫ/Ϫ mice, 6, 23 in this study, bone marrow transplantation reduced lesion areas in the aortic arches of HF-fed Ldlr Ϫ/Ϫ mice of both genotypes. Even though background levels of atherosclerosis were reduced in bone marrow-transplanted mice, chimeric Ldlr Ϫ/Ϫ mice with ACE2 deficiency in bone marrow-derived cells exhibited increased atherosclerosis of a magnitude (Ϸ2-fold) similar to that seen from whole body ACE2 deficiency. Moreover, chimeric mice with ACE2 deficiency in bone marrow-derived cells exhibited increased atherosclerosis in the absence of changes in the systemic RAS. These results suggest that local effects of ACE2 on bone marrow-derived cells, potentially macrophages, mediate effects of ACE2 deficiency to promote atherosclerosis.
Previous investigators demonstrated that adenoviral overexpression of murine ACE2 in rabbits subjected to endothelial injury and fed an atherogenic diet attenuated lesion progression. 16 Similarly, recent studies demonstrated that adenoviral overexpression of ACE2 in atherosclerotic lesions of rabbits attenuated fatty streak formation. 20 In ApoE Ϫ/Ϫ mice, adenoviral overexpression of ACE2 reduced atherosclerosis. 17 Moreover, recent studies demonstrated that whole body deficiency of ACE2 in ApoE Ϫ/Ϫ mice increased atherosclerosis. 18 In agreement with this, results from the present study demonstrate that whole body deficiency of ACE2 in Ldlr Ϫ/Ϫ mice increased atherosclerosis. Collectively, these results support a pivotal role for ACE2 in developing atherosclerotic lesions.
Our studies extend previous findings by contrasting the effects of whole body versus bone marrow deficiency of ACE2 on atherosclerosis. Our results demonstrate an increase of similar magnitude in lesion formation in whole body ACE2-deficient mice compared with chimeric mice lacking ACE2 in bone marrow-derived cells. Although these findings do not indicate a specific cell type responsible for augmented lesion formation in mice lacking ACE2 in bone marrow-derived cells, macrophage-rich regions of lesions from Ldlr Ϫ/Ϫ mice stained positive for ACE2. In addition, MPMs exhibited ACE2 enzymatic activity, and macrophages from ACE2-deficient mice released greater concentrations of Ang II. Recent studies demonstrated that aortas from ACE2deficient ApoE Ϫ/Ϫ mice exhibited increased cell adhesion when perfused with whole blood. 18 Moreover, bone marrowderived macrophages from ACE2-deficient mice exhibited increased expression of inflammatory cytokines in response to lipopolysaccharide. 18 Results from the present study demonstrate increased monocyte adhesion when HUVECs were cocultured with MPMs from ACE2-deficient mice, and extend previous findings by demonstrating that these effects are Ang II/AT 1 receptor mediated. 2 Moreover, in this study, in the absence of external stimuli (eg, lipopolysaccharide), 18 ACE2-deficient MPMs exhibited increased expression and release of inflammatory cytokines. These results demonstrate that deficiency of ACE2 in pivotal cell types promotes inflammation and monocyte adhesion, 2 mechanisms invoked in lesion formation.
In the setting of ACE2 deficiency, where Ang II is formed but not catabolized to Ang-(1-7), our results using losartan support a prominent role for Ang II effects at AT 1 receptors to augment atherosclerosis. In contrast, in wild-type mice, both Ang II and Ang-(1-7) are present to regulate lesion formation. Recent studies demonstrated that long-term infusion of Ang-(1-7) to ApoE Ϫ/Ϫ mice reduced atherosclerosis. 24 Moreover, recent studies demonstrated functional antagonism of Ang II-mediated regulation of smooth muscle cell proliferation and migration by Ang-(1-7), supporting functional interactions between these angiotensin peptides that are regulated by ACE2. 20 Similar to findings in smooth muscle cells, in the present study, although Ang-(1-7) had no effect on monocyte adhesion when incubated alone with HUVECs, this peptide functionally antagonized effects of Ang II to promote monocyte adhesion. Because the effects of Ang-(1-7) to blunt Ang II-induced monocyte adhesion were abolished by D-Ala, these findings implicate the mas receptor as the mediator of Ang-(1-7)-induced antagonism of Ang II. Infusion of Ang-(1-7) with Ang II markedly lowered atherosclerosis in Ldlr Ϫ/Ϫ mice, supporting an in vivo interplay between these ACE2-regulated angiotensin peptides in the development of atherosclerosis.
In conclusion, the present study demonstrated that whole body deficiency of endogenous ACE2, as well as deficiency in bone marrow-derived cells, increased atherosclerosis in Ldlr Ϫ/Ϫ mice. Elevated macrophage concentrations of Ang II in ACE2-deficient mice promoted expression of inflammatory cytokines and increased monocyte adhesion to endothelial cells. When both Ang II and Ang-(1-7) were present, Ang-(1-7) functionally antagonized effects of Ang II to promote monocyte adhesion and lesion development. These results demonstrate that regulation of local concentrations of Ang II versus Ang-(1-7) in pivotal cell types by enzymes such as ACE2 influences developing atherosclerotic lesions.
